Steven Dubinett, MD
Building on original discoveries relevant to inflammation and immunity in lung cancer, he developed a translational research program, which utilizes these laboratory-based discoveries in the translational and clinical environment. As a NCI Translational Research Working Group member, he participated in designing pathways to clinical goals. He previously served as Director for Biomarker Development for the American College of Surgeons Oncology Group, directing biospecimen utilization in the context of clinical trials. Dr. Dubinett serves as the Chair of the Research Evaluation Panel for biospecimen utilization for the American College of Radiology Imaging Network/ National Lung Screening Trial. He previously chaired the FDA Cellular, Tissue & Gene Therapies Advisory Committee and serves on the NCI Thoracic Malignancy Steering Committee as a Translational Science. Dr. Dubinett’s scientific interests include: lung cancer, immunobiology of lung cancer, translational research, human non-small cell lung cancer, pathogenesis of lung cancer, microenvironment, inflammation and epithelial mesenchymal transition.
Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, Walser TC, Salehi-Rad R, Yanagawa J, Lee JM, Sharma S, Aberle DR, Spira AE, Elashoff DA, Wallace WD, Fishbein MC, Dubinett SM; The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.; Cancer Research; 2019
Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett SM; Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.; Cancer Research; 2018
Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM; Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.; Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research; 2017
Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, Herschman H, Krysan K, Dubinett S; Chronic IL-1ß-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer.; Scientific Reports; 2020